Dunamu & Partners
VC Fund
Seoul, South Korea
Dunamu & Partners is a VC fund in Seoul focused on Software and FinTech. Dunamu & Partners is the professional investment arm of Dunamu, South Korea's leading fintech company which operates Upbit, Stockplus and Stockplus Unlisted. Dunamu & Partners primarily invests in the fintech, blockchain and AI/data/contents sector. Its investments are agnostic to industry, geography and size.
- Total investments:
- 70
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Dunamu & Partners invests in
Stages Dunamu & Partners invests in
Countries Dunamu & Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $669k–$5M
- Series A
- $1.2M–$22M
- Series B
- $3.3M–$23M
Investment Focus
Industry
- Software 16 (23%)
- FinTech 7 (10%)
- Financial Services 7 (10%)
- Gaming 6 (9%)
- Information Technology 6 (9%)
Stage
- Seed 19 (27%)
- Series B 15 (21%)
- Series A 11 (16%)
- Funding Round 7 (10%)
- Pre-Seed 3 (4%)
Country
- South Korea 28 (40%)
- United States 13 (19%)
- Canada 2 (3%)
- France 1 (1%)
- Thailand 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
JB Lee
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
|
Jeremy Nam
Co-Founder
|
Co-Founder | Total investments: 0 | Find email | |
|
Lee Kang-jun
CEO
|
CEO | Total investments: 1 | Find email | |
|
Steve Lee
Founder
|
Founder | Total investments: 0 | Find email | |
|
Steven Koo
Co-Founder
|
Co-Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Inocras
|
Inocras Inc. specializes in whole genome sequencing and analytics, focusing on providing insights for personalized care in cancer and rare diseases. Utilizing artificial intelligence, Inocras aims to revolutionize healthcare by enabling precision medicine. The company offers services to patients, healthcare providers, researchers, and partners,seeking to unlock new possibilities in precision health. With a commitment to innovation, Inocras has introduced products like CancerVision and RareVision, designed to enhance diagnosis and treatment strategies through comprehensive genomic analysis. | $20K / Series B / Jul 01, 2026 | |
AIRS Medical
|
AIRS Medical is an MRI reconstruction software service provider. | Private Equity / Jun 16, 2026 | |
Pasqal
|
PASQAL is developing a full-stack quantum computer that will be used to simulate complex phenomena for scientific discovery and to address general problems such as optimization, drug discovery, and machine learning. The company's quantum processing units are made up of hundreds of atomic qubits in 2D and 3D arrays, and their programmingenvironment, to address our customers' needs in quantum computing and simulation. | Venture - Series Unknown / Oct 29, 2025 | |
|
Yukhaekhan Project
|
Joyful Project operates a B2B mental healthcare platform. | Seed / Aug 08, 2025 | |
Nitra
|
Nitra offers expense management software that integrates with the banks to provide innovative loan products. | $22M / Series A / Aug 01, 2025 | |
Solomon
|
Solomon AI is a legal AI company backed by Bessemer building the next generation of artificially intelligent legal assistants. | $8.5M / Seed / Jul 23, 2025 | |
Botrista Technology
|
Botrista is a robotics company based in Silicon Valley. They provide an end to end beverage solution to F&B retail chains. They have the capability to automate drink menus and pour an array of drinks including delicious and high profitable non-alcoholic mixed beverages. The Robot Barista increases drink selection, quality, and consistency whilereducing labor. It can also be modified to mix premium cocktails.The Botrista Team combines decades of robotics expertise and beverage industry experience to develop end-to-end automation solutions to help beverage retailers address the shifting demands from today’s health-conscious consumer. It leverages manufacturing techniques and integrates software to revolutionize the way fresh beverages are prepared and produced. | $6.7M / Series C / May 23, 2025 | |
Glencoco
|
Glencoco is a B2B sales marketplace | $1.5M / Venture - Series Unknown / Oct 24, 2024 | |
|
AIRS Medical
|
AIRS Medical is an MRI reconstruction software service provider. | $19.5M / Series C / Jul 10, 2024 | |
Reliv
|
Reliv AI automates the testing necessary before deploying apps or online services for AI-powered enterprises. Reliv AI automatically evaluates the service's user interface and collects various aspects such as buttons and tabs on the screen as independent metadata. | Seed / Mar 29, 2024 | |
| See all 70 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Dunamu & Partners invest in?
Dunamu & Partners invests primarily in Software, FinTech and Financial Services startups, most often at Seed and Series B stage. Most of the 70 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Dunamu & Partners's check size?
Dunamu & Partners typically joins rounds of $669k–$5M at Seed, $1.2M–$22M at Series A and $3.3M–$23M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Dunamu & Partners participates in.
How do I contact Dunamu & Partners?
Public channels for Dunamu & Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Dunamu & Partners?
The team at Dunamu & Partners includes JB Lee (Co-Founder), Jeremy Nam (Co-Founder) and Lee Kang-jun (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
